A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Clinical trial NCT04389632 · RECRUITING

Trial details

NCT number: NCT04389632
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Carcinoma, Non-Small Cell Lung Squamous Cell Carcinoma of Head and Neck HER2 Negative Breast Neoplasms Esophageal Squamous Cell Carcinoma Esophageal Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Ovarian Neoplasms Cutaneous Squamous Cell Cancer Exocrine Pancreatic Adenocarcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms Stomach Neoplasms

Start date: 2020-06-08
Primary completion: 2027-06-16
Enrollment: 1006

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.